Research suggests that riboflavin has been identified in multiple reviews as a promising option for migraine prevention, with authors noting a favorable side effect profile compared to conventional pharmaceutical treatments. The available evidence base consists entirely of review articles rather than primary trials or meta-analyses, which limits the strength of conclusions that can be drawn; these reviews summarize and interpret existing clinical literature rather than generating new experimental data. Two of the three reviews express support for riboflavin's preventive role, with one noting it appears in clinical guidelines alongside established pharmaceutical options such as beta-blockers and valproate, while a third review covering major neurology organization guidelines found that recommendations across those bodies are inconsistent and sometimes contradictory regarding nutraceuticals as a category. Studies indicate that while the overall direction of evidence leans modestly in favor of riboflavin for migraine prevention, the mixed guideline consensus and absence of primary trial data in this summary suggest that readers should consult current clinical sources and healthcare providers for a more complete picture.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. | Review | 2016 | Mixed | 72 |
| Management of migraine: an algorithmic approach. | Review | 2000 | Supports | 67 |
| [Anti-migraine treatment: present and future]. | Review | 1999 | Supports | 62 |